Skip to content

Esperion hit by Amgen’s weak Repatha results

March 17, 2017

Esperion Therapeutics Inc ESPR 21.25% shares are trading lower by $5.10 (18 percent) at $24.55 in Friday’s session. It’s being dragged down by poor results from cholesterol drug testing that’s having a major negative impact on related stocks in the sector.

The primary catalyst for the biotech bashing is Amgen Inc. AMGN 6.38%. Shares are trading lower by $12.00 at $168.11, when results for Repatha didn’t meet Wall Street expectations.

In another sympathy move, Regeneron Pharmaceuticals REGN 2.72% shares are trading lower by $19.50 at $373.09.

While Amgen (lower by roughly 6 percent) and Regeneron (lower by over 4 percent) are struggling to recover, Esperion was hit hardest and has been attempting to rebound.

http://bit.ly/2mavxDr

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: